According to the company, its approach allows for improved detection of EV-bound proteins and phosphoproteins, which it is using for biomarker discovery.
In urothelial cancer, the presence of a gene signature stemming from stromal cells seemed to interfere with anti-PD-1 drug response in tumors with infiltrating T-cells.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
A PCR-based analysis of nearly 700 cases picked up human papillomavirus or human polyomaviruses DNA in a fraction of urothelial bladder carcinoma tumors.
